Low-dose DOX-polygodial nanosystem modulates the CD47/CALR axis for safer triple negative breast cancer treatment.

Hadir M Emara, Rana A Youness, Tamer M Manie, Anwar Abdelnaser, Nageh K Allam

Abstract read

In one paragraph

Article in Nanoscale advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hadir M EmaraNanotechnology Program, School of Sciences & Engineering, The American University in Cairo New Cairo 11835 Egypt Nageh.allam@aucegypt.edu.ORCID https://orcid.org/0009-0007-1820-9979

Rana A YounessMolecular Biology and Biochemistry Department, Molecular Genetics Research Team, Faculty of Biotechnology, German International University (GIU) New Administrative Capital 11835 Egypt.

Tamer M ManieBreast Surgery Department, National Cancer Institute, Faculty of Medicine, Cairo University Cairo Egypt.

Anwar AbdelnaserInstitute of Global Health and Human Ecology, School of Sciences and Engineering, AUC - American University in Cairo New Cairo Egypt anwar.abdelnaser@aucegypt.edu.

Nageh K AllamNanotechnology Program, School of Sciences & Engineering, The American University in Cairo New Cairo 11835 Egypt Nageh.allam@aucegypt.edu.ORCID https://orcid.org/0000-0001-9458-3507

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple Negative Breast Cancer (TNBC) is the most aggressive subtype of Breast Cancer (BC). Immunosurveillance significantly influences TNBC progression, drug resistance, and metastasis. Among its regulators, Cluster of Differentiation 47 (CD47) and calreticulin (CALR) play crucial roles. This study examined the mRNA expression of CD47 and CALR in breast cancer tissues from 25 patients compared to normal tissues and investigated their role in chemoresistance at sublethal drug doses. MDA-MB-231 cells were treated with doxorubicin (DOX), polygodial (PG), or both, and CD47/CALR expression was analyzed at sublethal concentrations determined

Identifiers

PMID41788762

DOI10.1039/d5na01082a

PMCPMC12959604

What Socratic holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.